Viral Respiratory Tract Infection Clinical Trial
Official title:
Acupuncture for Acute Viral Lower Respiratory Infection in Hospitalized Children: A Single Blinded Randomized Controlled Trial
| Verified date | June 2016 |
| Source | Ziv Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Israel: Ministry of Health |
| Study type | Interventional |
Acute viral respiratory infections are among the most common causes of hospitalization in the pediatric population. The usual presentation of viral respiratory tract infections (VRTI) includes fever, malaise, wheezing and or coughing, rhinorrhea and loss of appetite. Up to 50% of children will have at least one viral-induced wheezing illness by school age. Currently treatment of VRTI is essentially supportive and no specific and efficient treatments are known. Given the lack of effective medications, current treatment for severe viral lower respiratory tract infection (LRTI) in infants relies on supportive measures only. These measures include supplementation of oxygen, monitoring of apnea, nasal/gastric tube feeding or intravenous fluids, and, if required, respiratory support with nasal bi-level positive-airway pressure. VTRI therefore represent an important unmet need for improved treatment strategies. Acupuncture's effect on has also been studied. Acupuncture has been shown to be a safe and effective in various respiratory tract inflammations. A review published in 2011 have found that acupuncture is safe for pediatric patients. Acupuncture's effect on acute viral induced wheezing and cough in hospitalized children has yet to be studied. Since the current standard of care is supportive care only, using acupuncture as an additional treatment may provide benefit in reducing wheezing, respiratory distress, and shorten hospitalization.
| Status | Recruiting |
| Enrollment | 60 |
| Est. completion date | February 2018 |
| Est. primary completion date | February 2018 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 3 Months to 36 Months |
| Eligibility |
Inclusion Criteria: - The presence of acute viral respiratory disease Exclusion Criteria: - Evidence of chronic cardio-pulmonary disease, immune-suppression or any chronic systemic disease or disability |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Israel | Ziv Medical Center | Zefat |
| Lead Sponsor | Collaborator |
|---|---|
| Ziv Hospital |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | presence of fever | 5 days | No | |
| Primary | presence of cough | 5 days | No | |
| Primary | presence of rhinitis | 5 days | No | |
| Primary | symptoms of pharyngitis | 5 days | No | |
| Primary | presence of crepitations | 5 days | No | |
| Primary | presence of dyspnea or tachypnea | respiratory rate | 5 days | No |
| Primary | oxygen saturation | measured by (SpO2) | 5 days | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04815018 -
Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
|
||
| Completed |
NCT05093530 -
Safety and Tolerability of Single and Multiple Doses of Neumifil
|
Phase 1 | |
| Recruiting |
NCT06248983 -
Transmission Of Respiratory Tract microOrganisms In a School Environment
|
||
| Completed |
NCT05290792 -
Use of Wearable Sensors for Early Detection and Tracking of Viral Respiratory Tract Infections
|
N/A |